Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
What is your approach to managing rash associated with pirfenidone? Under what circumstances should the medication be temporarily held versus permanently discontinued?
Related Questions
How often are you performing CT screening in CVID patients to screen for ILD?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
What is your approach to managing ILD associated with inflammatory bowel disease?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
What strategies are effective for managing cough in patients receiving inhaled treprostinil?
What is your approach to counseling and managing patients with LAM desiring pregnancy?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
How do you approach pre-operative risk assessment and optimization in a patient with interstitial lung disease?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
